Press Release

Press Release - Q4FY26 - Consolidated Q4 revenue 37.7bn INR +15.8% y-y; EBITDA 7.6bn INR (margin 20.2%); PAT 3.0bn INR (margin 7.6%) - FY26 consolidated revenue 169.8bn INR +27.5% y-y; EBITDA 45.7bn INR (margin 26.9%); PAT 13.6bn INR (margin 7.8%) - AbbVie licensing deal for ISB 2001 with 700m USD upfront, total potential 1.925bn USD; Glenmark leads Emerging Markets commercialization - Strong US respiratory generics growth with first generic FloVent HFA approval and Fluticasone Nasal Spray OTC approval - RYALTRIS sales grew >50% globally; launched in US, China, Thailand; oncology portfolio expanded with new in-licensing - Monroe facility FDA clearance enables injectable manufacturing restart - India business outperformed IPM, ranked 2nd fastest growing among top 15 companies